

Oncology Today with Dr Neil Love: PARP Inhibitors in Breast Cancer Edition
(Video Presentation)

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. The OlympiAD trial comparing olaparib to treatment of physician's choice for patients with a germline BRCA mutation and HER2-negative metastatic breast cancer (mBC) demonstrated which outcome in terms of overall survival with olaparib in the overall population?

 - a. A statistically significant improvement
 - b. No statistically significant improvement
2. Results from the placebo-controlled Phase III BROCADE 3 trial demonstrated a progression-free survival benefit with which of the following PARP inhibitors in combination with carboplatin/paclitaxel for patients with HER2-negative mBC with germline BRCA mutations?

 - a. Olaparib
 - b. Talazoparib
 - c. Veliparib
 - d. Niraparib
3. The Phase III OlympiA trial is evaluating olaparib for patients with high-risk HER2-negative breast cancer and germline BRCA1/2 mutations in which setting?

 - a. Neoadjuvant
 - b. Adjuvant
 - b. Metastatic
4. Which of the following statements is true regarding the objective response rate (ORR) at week 12 in the MEDIOLA trial evaluating olaparib in combination with durvalumab for patients with mBC and germline BRCA1/2 mutations?

 - a. ORR was similar to that observed in the olaparib monotherapy arm of the OlympiAD trial
 - b. ORR was significantly higher than that observed in the olaparib monotherapy arm of the OlympiAD trial
 - c. ORR was significantly lower than that observed in the olaparib monotherapy arm of the OlympiAD trial